Varda Space: Revolutionizing Pharmaceutical Manufacturing in Space
Pharmaceutical scientists face a significant challenge on Earth due to the limitations imposed by gravity. However, Varda Space is on a mission to change the game. The company has recently secured a substantial amount of funding to leverage space as the ultimate frontier for producing critical pharmaceutical components that can be utilized to create essential drugs back on Earth.
Varda Space’s latest $187 million Series C funding round is earmarked for the development of a state-of-the-art laboratory facility in El Segundo, California. This facility is poised to revolutionize Varda’s orbital manufacturing process, potentially turning it into a lucrative source of intellectual property.
The 10,000-square-foot lab space will serve as a hub for Varda’s pharmaceutical scientists to identify top biologics, such as proteins and antibodies, that hold promise for space-based crystallization. By conducting meticulous research and testing, the team aims to determine the most suitable candidates for an orbital mission and the optimal conditions for their crystallization in space.
Through strategic partnerships with leading pharmaceutical manufacturers, Varda Space hopes to address specific industry challenges, including ingredient crystallization, drug purity issues, and shelf-life stability. The company’s goal is to leverage its lab and orbital spacecraft to solve these problems, ultimately generating valuable intellectual property that can be patented and licensed to drugmakers.
With the launch of the new laboratory, Varda anticipates a surge in patent filings, paving the way for future innovations in drug production. The recent funding round was led by prominent firms like Natural Capital and Shrug Capital, with contributions from notable investors such as Peter Thiel, Lux Capital, Khosla Ventures, and Caffeinated Capital.
Since 2023, Varda Space has successfully completed three missions and plans to undertake four more missions this year alone. The company has transitioned from using Rocket Lab-made spacecraft to developing its spacecraft in-house, with a goal of doubling its manufacturing output next year.
In addition to its pharmaceutical endeavors, Varda Space generates revenue by repurposing its spacecraft as a hypersonic flight testbed for the U.S. Department of Defense. By offering a more efficient and cost-effective approach to hypersonic flight testing, Varda has positioned itself as a key player in the aerospace industry.